Low insulin-like growth factor binding protein-2 expression is responsible for increased insulin receptor substrate-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis

被引:14
|
作者
Fornoni, A
Rosenzweig, SA
Lenz, O
Rivera, A
Striker, GE
Elliot, SJ
机构
[1] Univ Miami, Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA
[2] Univ Miami, Sch Med, Miller Sch Med, Vasc Biol Inst, Miami, FL 33136 USA
[3] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA
[4] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
关键词
D O I
10.1210/en.2006-0066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mesangial cells ( MC) isolated from glomerulosclerosis-prone ragged, olygosyndactilism, pintail (ROP) mice retain a stable phenotype after exposure to elevated glucose concentrations, whereas MC from glomerulosclerosis-resistant C57BL/6 (C) mice do not. In NOD and db/db mice, the stable phenotype induced by diabetes consists of autocrine activation of the IGF-I signaling pathway. We hypothesized that high ambient glucose activates the IGF-I pathway in ROP but not in C MC. MC were propagated in either 6 or 25 mM glucose. Isolated murine glomeruli were used to confirm in vitro experiments. 25 mM glucose induced increased insulin receptor substrate (IRS)-1 phosphorylation in ROP but not CMC. However, IGF-I, IGF-I receptor, and IRS-1 protein levels were induced by exposure to 25mM glucose in both cell lines. This occurred without a change in IGF-I binding sites, suggesting a role for IGF binding protein ( IGFBP). ROP MC and glomeruli expressed less IGFBP-2 than C MC and glomeruli. Addition of exogenous IGFBP-2 partially blunted the effect of 25mM glucose on IRS-1 phosphorylation in ROP MC. Renal biopsies from patients with diabetic nephropathy also showed markedly decreased IGFBP-2 expression when compared with patients without nephropathy. In summary, glucose induces IRS-1 phosphorylation in MC isolated from ROP mice susceptible to glomerulosclerosis. IGFBP-2 expression was low in ROP MC and glomeruli from patients with diabetic nephropathy, suggesting that this may represent a new marker of susceptibility to diabetic nephropathy. Finally, addition of exogenous IGFBP-2 in ROP MC partially blunted the effect of high glucose on IRS-1 phosphorylation and might have a protective role.
引用
收藏
页码:3547 / 3554
页数:8
相关论文
共 50 条
  • [31] Insulin-like growth factor binding protein-2 (IGFBP-2) action in cancer cells
    Russo, Vincenzo C.
    ENDOCRINE JOURNAL, 2010, 57 : S281 - S281
  • [32] INSULIN-LIKE GROWTH-FACTOR-2 AND INSULIN-LIKE GROWTH-FACTOR BINDING-PROTEIN-2 EXPRESSION IN HEPATOBLASTOMA
    AKMAL, SN
    YUN, K
    MACLAY, J
    HIGAMI, Y
    IKEDA, T
    HUMAN PATHOLOGY, 1995, 26 (08) : 846 - 851
  • [33] Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling
    Grimberg, Adda
    Coleman, Carrie M.
    Shi, Zonggao
    Burns, Timothy F.
    MacLachlan, Timothy K.
    Wang, Wenge
    El-Deiry, Wafik S.
    CANCER BIOLOGY & THERAPY, 2006, 5 (10) : 1408 - 1414
  • [34] Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding
    Hobba, GD
    Löthgren, A
    Holmberg, E
    Forbes, BE
    Francis, GL
    Wallace, JC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (31) : 19691 - 19698
  • [35] TUMOR HYPOGLYCEMIA IS NOT DUE TO ABNORMAL BINDING OF INSULIN-LIKE GROWTH FACTOR-II PRECURSOR TO INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-2
    BACH, LA
    PERDUE, JF
    HUDGINS, WR
    RECHLER, MM
    CLINICAL RESEARCH, 1992, 40 (02): : A166 - A166
  • [36] Activation-dependent expression of the insulin-like growth factor binding protein-2 in human lymphocytes
    Föll, JL
    Dannecker, L
    Zehrer, C
    Hettmer, S
    Berger, J
    Elmlinger, M
    Niethammer, D
    Ranke, MB
    Dannecker, GE
    IMMUNOLOGY, 1998, 94 (02) : 173 - 180
  • [37] Overexpression of insulin-like growth factor binding protein-2 in mice protects against the development of obesity, insulin resistance and hypertension
    Wheatcroft, S
    Crossey, P
    Ezzat, V
    Williams, S
    Modo, M
    Miell, J
    Shah, A
    Kearney, M
    ATHEROSCLEROSIS, 2005, 181 (01) : S5 - S5
  • [38] The effect of insulin-like growth factor-I on the proliferation of human breast cancer cells in vitro and on the secretion of insulin-like growth factor binding protein-2
    Maxwell, P
    van den Berg, HW
    BRITISH JOURNAL OF CANCER, 1998, 78 : 13 - 13
  • [39] Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer
    Schnarr, B
    Strunz, K
    Ohsam, J
    Benner, A
    Wacker, J
    Mayer, D
    INTERNATIONAL JOURNAL OF CANCER, 2000, 89 (06) : 506 - 513
  • [40] Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance
    Janice M. Knowlden
    Helen E. Jones
    Denise Barrow
    Julia M. W. Gee
    Robert I. Nicholson
    Iain R. Hutcheson
    Breast Cancer Research and Treatment, 2008, 111 : 79 - 91